Adjuvant Effect of Bacille Calmette–Guérin on Hepatitis B Vaccine Immunogenicity in the Preterm and Term Newborn
Open Access
- 24 January 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 29
Abstract
Immunization is key to protecting term and preterm infants from a heightened risk of infection. However, preterm immunity is distinct from that of the term, limiting its ability to effectively respond to vaccines routinely given at birth, such as hepatitis B vaccine (HBV). As part of the Expanded Program on Immunization, HBV is often given together with the live-attenuated vaccine Bacille Calmette–Guérin (BCG), known to activate multiple pattern-recognition receptors. Of note, some clinical studies suggest BCG can enhance efficacy of other vaccines in term newborns. However, little is known about whether BCG can shape Th-polarizing cytokine responses to HBV nor the age-dependency of such effects, including whether they may extend to the preterm. To characterize the effects of BCG on HBV immunogenicity, we studied individual and combined administration of these vaccines to cord newborn and adult human whole blood and mononuclear cells in vitro and to neonatal and adult mice in vivo. Compared to either BCG or HBV alone, (BCG + HBV) synergistically enhanced in vitro whole blood production of IL-1β, while (BCG + HBV) also promoted production of several cytokines/chemokines in all age groups, age-specific enhancement included IL-12p70 in the preterm and GM-CSF in the preterm and term. In human mononuclear cells, (BCG + HBV) enhanced mRNA expression of several genes including CSF2, which contributed to clustering of genes by vaccine treatment via principle component analysis. To assess the impact of BCG on HBV immunization, mice of three different age groups were immunized subcutaneously with, BCG, HBV, (BCG + HBV) into the same site; or BCG and HBV injected into separate sites. Whether injected into a separate site or at the same site, co-administration of BCG with HBV significantly enhanced anti-HBV IgG titers in mice immunized on day of life-0 or -7, respectively, but not in adult mice. In summary, our data demonstrate that innate and adaptive vaccine responses of preterm and term newborns are immunologically distinct. Furthermore, BCG or “BCG-like” adjuvants should be further studied as a promising adjuvantation approach to enhance immunogenicity of vaccines to protect these vulnerable populations.Keywords
Funding Information
- National Institutes of Health (1R01AI100135-01, 3R01AI067353-05S1, 1U01AI124284-01, HHSN272201400052C, U19AI118608)
- Bill and Melinda Gates Foundation (OPPGH5284, OPP1035192)
This publication has 80 references indexed in Scilit:
- A Neonatal Model of Intravenous Staphylococcus epidermidis Infection in Mice <24 h Old Enables Characterization of Early Innate Immune ResponsesPLOS ONE, 2012
- Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000The Lancet, 2012
- Concomitant Administration of Mycobacterium bovis BCG with the Meningococcal C Conjugate Vaccine to Neonatal Mice Enhances Antibody Response and Protective EfficacyClinical and Vaccine Immunology, 2011
- Variables to be controlled in the assessment of blood innate immune responses to Toll-like receptor stimulationJournal of Immunological Methods, 2011
- Profound Lack of Interleukin (IL)–12/IL‐23p40 in Neonates Born Early in Gestation Is Associated with an Increased Risk of SepsisThe Journal of Infectious Diseases, 2010
- TLR2 Mediates Recognition of Live Staphylococcus epidermidis and Clearance of BacteremiaPLOS ONE, 2010
- Mincle is a long sought receptor for mycobacterial cord factorJournal of Experimental Medicine, 2009
- IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiationProceedings of the National Academy of Sciences, 2009
- The β-glucan receptor dectin-1 functions together with TLR2 to mediate macrophage activation by mycobacteriaBlood, 2006
- Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cellsBlood, 2006